MedicalJane

JUNE 29, 2018

Although this is exciting for many advocates of the plant, many patients that are suffering from ailing health conditions are left wondering what this means for them, and how exactly all of these changes will impact their healthcare options. Do you qualify for medical cannabis? Do you qualify for medical cannabis? Check it out here.

Patients 83

Patients Legalization Conditions Treatment 83

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 51

DEA Clinical Trials THC Research and Development 51

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

CannaMD

NOVEMBER 15, 2020

His findings are sure to alarm medical cannabis professionals and patients alike. research on marijuana harms – such as cannabis withdrawal, treatments for substance abuse and use/exposure during pregnancy or infancy – received 20 times more funding than research on cannabis therapeutics. funders use their money for cannabis research.

DEA 105

DEA Clinical Trials Cannabinoids Treatment 105

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. ”, our first instinct is to remain patients that CBD is CBD.

CBD 105

CBD DEA Research and Development Hemp 105

Cannabis Law Report

JUNE 10, 2021

(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 85

DEA Hemp Cultivation Advocacy 85

Cannabis Law Report

OCTOBER 4, 2021

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”.

DEA 45

DEA Pharmaceutical Research and Development Compliance 45

Cannabis Law Report

NOVEMBER 20, 2021

he Alabama State Board of Medical Examiners Thursday announced draft rules to govern how physicians can recommend medical cannabis to eligible patients. The draft rules would require physicians to obtain an annual certification permit from the Alabama Board of Medical Examiners if they want to recommend a patient to use medical cannabis.

Patients 52

Patients DEA Dispensary Conditions 52

CannaMD

NOVEMBER 20, 2020

a wealth of new research legitimizing marijuana’s role in patient care – here we are. Making matters worse, there’s only one farm in the entire country with DEA approval to cultivate marijuana for research purposes. For more details, see: Best Cannabis Disorder Treatment? More Cannabis. Entry or Exit Drug? Get Started.

Therapy 104

Therapy Treatment DEA CBD 104

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

The Cannigma

MAY 16, 2025

The successes of cannabis businesses are now a part of the mainstream conversation and considered big business, while the rights and protections for medical cannabis patients have been sidelined. So while a cannabis business can join their local chamber of commerce, a patient in hospice can be denied access to medical cannabis.

Policy 92

Policy Advocacy Access Patients 92

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. See Deborah Brauser, FDA Permits Psilocybin to Be Tested for Refractory Depression, MEDSCAPE (Oct.

Law 81

Law Therapy Clinical Trials Decriminalization 81

CannaMD

MAY 6, 2020

However, given rapidly evolving – and often complicated – laws surrounding medical marijuana, many patients feel overwhelmed. In practice, the chances of feds or the DEA sitting at the border waiting to catch someone – that’s just not happening. Visiting Qualifying Patients. Planning a vacation should be fun.

Hash 105

Hash Legalization Marijuana Concentrates 105

Veriheal

DECEMBER 28, 2021

D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted. Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

The Cannigma

MAY 1, 2023

2 3 As clinical trials around the world proceeded in the late 1960s and 1970s, patients began reporting difficulty tolerating ketamine’s unpleasant hallucinogenic and dissociative properties. It was also after the Vietnam War that widespread ketamine abuse would begin to show up as a party drug. 9 How is ketamine commonly used?

Blood Pressure 98

Blood Pressure Chronic Pain Research and Development Clinical Trials 98

SpeedWeed

MARCH 28, 2021

That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”. As a result, there has been more interest among patients, clinicians, and researchers to see if cannabis is effective in treating PTSD. . Many veterans with PTSD already use cannabis to self-treat their symptoms.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

The Cannigma

MAY 6, 2021

Other than serving as a lighter version of delta-9-THC, delta-8 has also been researched as a potential treatment for a number of medical conditions and symptoms such as vomiting and nausea, glaucoma, pain, and inflammation. The vast majority of scientific knowledge is based on animal studies, however.

THC 145

THC Cannabinoids Concentrates Hemp 145

SpeedWeed

AUGUST 8, 2021

If all goes according to plan, patients will receive Sativex and the temozolomide chemotherapy drug, temozolomide on its own, or a placebo. In other positive news on this front, earlier this year the DEA announced that additional US companies would be allowed to supply scientists with cannabis for scientific research.

Cannabinoids 64

Cannabinoids Pharmaceutical DEA Medicine 64

United Patients Group

APRIL 3, 2023

A recommendation from a physician is simply permission (‘recommendation’) for the patient to use cannabis, which can be obtained in any state where medical marijuana is legal. Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019.

DEA 52

DEA Patients Conditions Cannabis 52

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. These designations indicate that psychedelics may represent substantial improvements over existing treatments for mental health conditions.

Law 81

Law Research and Development Therapy DEA 81

Veriheal

MAY 13, 2022

According to the Drug Enforcement Administration (DEA) website , magic mushrooms are recognizable by their slender stems, which are “topped by caps with dark gills on the underside.” Once consumed—whether fresh or dried in the form of a brewed tea or an edible—this hallucinogenic chemical transforms into psilocin.

Research and Development 98

Research and Development Legalization Consumption Microdosing 98

Veriheal

MAY 6, 2022

Millions of post-traumatic stress disorder (PTSD) patients around the world—such as ex-veterans and military servicemen—tend to relive their traumatic flashbacks and experiences during sleep. These promising findings offer a ray of hope for patients who battle regular nightmares.

Sleep 98

Sleep Cannabinoids THC CBD 98

The Blunt Truth

DECEMBER 22, 2023

UNITED STATES ATTORNEYS Attorney General Merrick Garland and DEA Administrator Anne Milgram received a letter this week from several former United States Attorneys. The letter raises concerns about the potential for abuse, a lack of medical treatment potential, and trafficking by criminal gangs. Look for more on this in 2024 also.

DEA 52

DEA Retail Programs Hemp 52

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. According to the DEA order, because the drug was recently approved by the FDA, it is now considered to have an accepted medical use.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

SpeedWeed

JULY 23, 2021

Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinical trials. The license only allows MedPharm to conduct research on cannabis that was shifted through certain channels that have been approved by the government and DEA.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

NewsMunchies

SEPTEMBER 5, 2018

A new marijuana-derived drug to treat rare forms of severe epilepsy in children will cost about $32,500 per patient, per year. Food and Drug Administration (DEA), contains the active ingredient cannabidiol (CBD) but it does not contain psychoactive molecule THC, which generates the marijuana high. “We

Supply Chain 40

Supply Chain DEA Pharmaceutical Chronic Pain 40

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. Tweet this. However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

MARCH 21, 2019

Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. Georgia only allows patients diagnosed with cancer, ALS, seizures, and other serious medical conditions to legally possess CBD. Texas allows the use of CBD for epileptic patients.

State Laws 55

State Laws Law CBD Legalization 55

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

SpeedWeed

MAY 15, 2021

For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. For 88% of people who receive this treatment, we can expect to see a treatment response. The subjects were randomly divided into two groups, each of which received three individual sessions of talk therapy.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

SpeedWeed

AUGUST 11, 2021

Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. This trial will be the second of its kind to be conducted so far, and one that is an FDA- and DEA-regulated double-blind, placebo-controlled study.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Canna Law Blog

SEPTEMBER 28, 2019

Not long ago we wrote about a decision by the Second Circuit that may force the DEA to re- or deschedule marijuana after writing about the lawsuit when it was first filed last year. Student visited the emergency room frequently when these were the only medical treatments she took. From immigration to waste dumping.

Education 83

Education Oil DEA Law 83

Veriheal

OCTOBER 23, 2020

House Republicans supported her proposal to defund the DEA and divert those funds to opioid treatment programs. . Patients in Virginia have been waiting and waiting for this day and it’s finally here! Next in news, medical cannabis is now available for purchase in Virginia! .

DEA 52

DEA Dispensary Programs Decriminalization 52